A citation-based method for searching scientific literature

Joonil Jung, Kexiang Xu, Derek Lessing, Nancy M Bonini. Hum Mol Genet 2009
Times Cited: 43



Ulrike Bichelmeier, Thorsten Schmidt, Jeannette Hübener, Jana Boy, Lukas Rüttiger, Karina Häbig, Sven Poths, Michael Bonin, Marlies Knipper, Werner J Schmidt, Johannes Wilbertz, Hartwig Wolburg, Franco Laccone, Olaf Riess. J Neurosci 2007
Times Cited: 133




List of shared articles



Times cited


Cerebellar soluble mutant ataxin-3 level decreases during disease progression in Spinocerebellar Ataxia Type 3 mice.
Huu Phuc Nguyen, Jeannette Hübener, Jonasz Jeremiasz Weber, Stephan Grueninger, Olaf Riess, Andreas Weiss. PLoS One 2013
13

Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.
Carlos A Matos, Sandra de Macedo-Ribeiro, Ana Luísa Carvalho. Prog Neurobiol 2011
89

Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3).
Jeannette Hübener, Jonasz Jeremiasz Weber, Claudia Richter, Lisa Honold, Andreas Weiss, Fabronia Murad, Peter Breuer, Ullrich Wüllner, Peter Bellstedt, Francois Paquet-Durand,[...]. Hum Mol Genet 2013
54

Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies.
Melvin M Evers, Lodewijk J A Toonen, Willeke M C van Roon-Mom. Mol Neurobiol 2014
48

Polyglutamine spinocerebellar ataxias: emerging therapeutic targets.
Andreia Neves-Carvalho, Sara Duarte-Silva, Andreia Teixeira-Castro, Patrícia Maciel. Expert Opin Ther Targets 2020
3

Identification of the calpain-generated toxic fragment of ataxin-3 protein provides new avenues for therapy of Machado-Joseph disease| Spinocerebellar ataxia type 3.
Ana Teresa Simões, Vítor Carmona, Joana Duarte-Neves, Janete Cunha-Santos, Luís Pereira de Almeida. Neuropathol Appl Neurobiol 2021
0

Molecular Mechanisms and Cellular Pathways Implicated in Machado-Joseph Disease Pathogenesis.
Clévio Nóbrega, Ana Teresa Simões, Joana Duarte-Neves, Sónia Duarte, Ana Vasconcelos-Ferreira, Janete Cunha-Santos, Dina Pereira, Magda Santana, Cláudia Cavadas, Luís Pereira de Almeida. Adv Exp Med Biol 2018
9

N-terminal ataxin-3 causes neurological symptoms with inclusions, endoplasmic reticulum stress and ribosomal dislocation.
Jeannette Hübener, Franz Vauti, Claudia Funke, Hartwig Wolburg, Yihong Ye, Thorsten Schmidt, Karen Wolburg-Buchholz, Ina Schmitt, Adriane Gardyan, Stefan Driessen,[...]. Brain 2011
39

From Pathogenesis to Novel Therapeutics for Spinocerebellar Ataxia Type 3: Evading Potholes on the Way to Translation.
Jorge Diogo Da Silva, Andreia Teixeira-Castro, Patrícia Maciel. Neurotherapeutics 2019
16

CDK5 protects from caspase-induced Ataxin-3 cleavage and neurodegeneration.
Jan Liman, Sebastian Deeg, Aaron Voigt, Hannes Voßfeldt, Christoph P Dohm, André Karch, Jochen Weishaupt, Jörg B Schulz, Mathias Bähr, Pawel Kermer. J Neurochem 2014
16

Gene Therapy for Neurodegenerative Diseases: Slowing Down the Ticking Clock.
Raygene Martier, Pavlina Konstantinova. Front Neurosci 2020
7

The Mechanisms of Nuclear Proteotoxicity in Polyglutamine Spinocerebellar Ataxias.
Davin Lee, Yun-Il Lee, Young-Sam Lee, Sung Bae Lee. Front Neurosci 2020
3

Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease.
Ana T Simões, Nélio Gonçalves, Arnulf Koeppen, Nicole Déglon, Sebastian Kügler, Carlos Bandeira Duarte, Luís Pereira de Almeida. Brain 2012
80

Human Induced Pluripotent Stem Cell-Based Modelling of Spinocerebellar Ataxias.
Marina P Hommersom, Ronald A M Buijsen, Willeke M C van Roon-Mom, Bart P C van de Warrenburg, Hans van Bokhoven. Stem Cell Rev Rep 2021
0

Animal Models of Machado-Joseph Disease.
Jana Schmidt, Thorsten Schmidt. Adv Exp Med Biol 2018
0

Neuron-specific proteotoxicity of mutant ataxin-3 in C. elegans: rescue by the DAF-16 and HSF-1 pathways.
Andreia Teixeira-Castro, Michael Ailion, Ana Jalles, Heather R Brignull, João L Vilaça, Nuno Dias, Pedro Rodrigues, João F Oliveira, Andreia Neves-Carvalho, Richard I Morimoto,[...]. Hum Mol Genet 2011
67

From pathways to targets: understanding the mechanisms behind polyglutamine disease.
Jonasz Jeremiasz Weber, Anna Sergeevna Sowa, Tina Binder, Jeannette Hübener. Biomed Res Int 2014
34

Therapeutic prospects for spinocerebellar ataxia type 2 and 3.
Ilya Bezprozvanny, Thomas Klockgether. Drugs Future 2009
14

RNA therapy for polyglutamine neurodegenerative diseases.
Lauren M Watson, Matthew J A Wood. Expert Rev Mol Med 2012
10

Mouse models of spinocerebellar ataxia type 3 (Machado-Joseph disease).
Veronica F Colomer Gould. Neurotherapeutics 2012
23

Toward understanding Machado-Joseph disease.
Maria do Carmo Costa, Henry L Paulson. Prog Neurobiol 2012
157

Proteolytic Cleavage of Polyglutamine Disease-Causing Proteins: Revisiting the Toxic Fragment Hypothesis.
Carlos A Matos, Luis Pereira de Almeida, Clevio Nobrega. Curr Pharm Des 2017
16